Detecting genetic changes caused by harmful substances
Error-suppressed whole genome sequencing for genotoxicant-induced structural variant detection
This study is looking at how harmful substances can change our DNA and aims to create better tests to help people understand their genetic risks for cancer and other diseases caused by these exposures.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10590370 on NIH RePORTER |
What this research studies
This research focuses on identifying structural variants in the human genome that are caused by exposure to genotoxicants, which are harmful substances that can damage DNA. By using advanced whole genome sequencing techniques, the project aims to develop more accurate assays that can pinpoint specific genetic alterations resulting from these exposures. This could help in understanding how these changes contribute to cancer and other genetic diseases. Patients may benefit from improved diagnostic tools that can better assess their genetic risks related to environmental exposures.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of exposure to genotoxicants or those with genetic predispositions to cancer.
Not a fit: Patients who do not have a history of exposure to harmful substances or genetic predispositions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better detection of genetic changes that increase cancer risk, allowing for earlier interventions and personalized treatment strategies.
How similar studies have performed: Other research has shown success in using advanced genomic techniques to identify genetic alterations, indicating that this approach has potential for meaningful advancements.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wilson, Thomas Edward — University of Michigan at Ann Arbor
- Study coordinator: Wilson, Thomas Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.